GTx-758
GTx-758 is an investigational drug developed for the treatment of prostate cancer. It is a nonsteroidal selective estrogen receptor alpha agonist (SERAA) that works by reducing the levels of testosterone in the body, which is a key driver of prostate cancer growth.
Mechanism of Action[edit | edit source]
GTx-758 functions by selectively activating the estrogen receptor alpha (ERα) in the pituitary gland and hypothalamus. This activation leads to a decrease in the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn reduces the production of testosterone by the testes. Lower testosterone levels can help slow the progression of prostate cancer.
Clinical Development[edit | edit source]
GTx-758 has undergone several clinical trials to evaluate its safety and efficacy in patients with prostate cancer. These trials have shown that GTx-758 can effectively lower testosterone levels without the need for androgen deprivation therapy (ADT), which is commonly associated with significant side effects such as hot flashes, osteoporosis, and loss of libido.
Potential Benefits[edit | edit source]
The use of GTx-758 offers several potential benefits over traditional ADT. By selectively targeting ERα, GTx-758 may reduce the risk of side effects commonly associated with ADT. Additionally, GTx-758 has been shown to maintain bone density and improve quality of life in patients undergoing treatment for prostate cancer.
Side Effects[edit | edit source]
As with any medication, GTx-758 may cause side effects. Common side effects observed in clinical trials include gynecomastia, nausea, and fatigue. However, these side effects are generally considered to be less severe than those associated with traditional ADT.
Current Status[edit | edit source]
As of the latest updates, GTx-758 is still under investigation and has not yet received approval from regulatory authorities such as the Food and Drug Administration (FDA) for general use in the treatment of prostate cancer. Ongoing research aims to further establish its safety profile and therapeutic efficacy.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
-
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
